Marina N Nikiforova

List of Publications by Year in descending order

97 papers	16,406 citations	34016 52 h-index	38300 95 g-index
98 all docs	98 docs citations	98 times ranked	14579 citing authors

#	Article	IF	Citations
1	Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut, 2022, 71, 961-973.	6.1	60
2	Molecular profiling of papillary thyroid carcinomas in healthcare workers exposed to low dose radiation at the workplace. Endocrine, 2022, 76, 95.	1.1	0
3	Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations. Endocrine-Related Cancer, 2022, 29, 467-473.	1.6	6
4	Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing. Endocrine-Related Cancer, 2022, 29, 513-520.	1.6	2
5	Evaluation of the Molecular Landscape of Pediatric Thyroid Nodules and Use of a Multigene Genomic Classifier in Children. JAMA Oncology, 2022, 8, 1323.	3.4	21
6	Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. Cancer Cytopathology, 2021, 129, 33-42.	1.4	30
7	Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples. Thyroid, 2021, 31, 589-595.	2.4	19
8	Prevalence and Spectrum of DICER1 Mutations in Adult-onset Thyroid Nodules with Indeterminate Cytology. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e968-e977.	1.8	26
9	Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched caseâ€control study. Cancer, 2021, 127, 1779-1787.	2.0	38
10	Clinicopathologic Characteristics of Thyroid Nodules Positive for theTHADA-IGF2BP3Fusion on Preoperative Molecular Analysis. Thyroid, 2021, 31, 1212-1218.	2.4	16
11	Molecular alterations in HÃ¼rthle cell nodules and preoperative cancer risk. Endocrine-Related Cancer, 2021, 28, 301-309.	1.6	23
12	Targeted next-generation sequencing supports serrated epithelial change as an early precursor to inflammatory bowel diseaseâ€“associated colorectal neoplasia. Human Pathology, 2021, 112, 9-19.	1.1	8
13	Can TP53-mutant follicular adenoma be a precursor of anaplastic thyroid carcinoma?. Endocrine-Related Cancer, 2021, 28, 621-630.	1.6	6
14	Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. Gut, 2020, 69, 52-61.	6.1	108
15	Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas andÂBile Duct. Gastroenterology, 2020, 158, 573-582.e2.	0.6	110
16	The histopathology of SPINK1-associated chronic pancreatitis. Pancreatology, 2020, 20, 1648-1655.	0.5	7
17	KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy. Modern Pathology, 2020, 33, 1832-1843.	2.9	18
18	Is Next-Generation Sequencing Alone Sufficient to Reliably Diagnose Gliomas?. Journal of Neuropathology and Experimental Neurology, 2020, 79, 763-766.	0.9	6

#	Article	IF	Citations
19	Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer. Cancer Medicine, 2019, 8, 5831-5839.	1.3	57
20	Characterization of Activating Mutations of the MEK1 Gene in Papillary Thyroid Carcinomas. Thyroid, 2019, 29, 1279-1285.	2.4	7
21	Interactive Browser-Based Genomics Data Visualization Tools for Translational and Clinical Laboratory Applications. Journal of Molecular Diagnostics, 2019, 21, 985-993.	1.2	7
22	GLIS rearrangements in thyroid nodules: A key to preoperative diagnosis of hyalinizing trabecular tumor. Cancer Cytopathology, 2019, 127, 560-566.	1.4	21
23	Clinical Utility of GlioSeq Next-Generation Sequencing Test in Pediatric and Young Adult Patients With Brain Tumors. Journal of Neuropathology and Experimental Neurology, 2019, 78, 694-702.	0.9	3
24	MiRNAs Are Involved in Tall Cell Morphology in Papillary Thyroid Carcinoma. Cancers, 2019, 11, 885.	1.7	10
25	Consistency and reproducibility of nextâ€generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathology, 2019, 127, 285-296.	1.4	39
26	Targeted mutation detection in breast cancer using MammaSeqâ„¢. Breast Cancer Research, 2019, 21, 22.	2.2	28
27	Benign call rate and molecular test result distribution of ThyroSeq v3. Cancer Cytopathology, 2019, 127, 161-168.	1.4	50
28	Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology. JAMA Oncology, 2019, 5, 204.	3.4	317
29	GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. Thyroid, 2019, 29, 161-173.	2.4	69
30	Characterization of thyroid cancer driven by known and novel ALK fusions. Endocrine-Related Cancer, 2019, 26, 803-814.	1.6	38
31	Incidental Diagnosis of Parathyroid Lesions by Preoperative Use of Nextâ€Generation Molecular Testing. World Journal of Surgery, 2018, 42, 2840-2845.	0.8	2
32	Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times. Gastroenterology, 2018, 154, 2060-2063.e8.	0.6	69
33	Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer, 2018, 124, 1682-1690.	2.0	274
34	Authors' Reply. Journal of Molecular Diagnostics, 2018, 20, 125-126.	1.2	1
35	Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer. Journal of the National Cancer Institute, 2018, 110, 371-378.	3.0	52
36	Cancer risk and clinicopathological characteristics of thyroid nodules harboring thyroidâ€stimulating hormone receptor gene mutations. Diagnostic Cytopathology, 2018, 46, 369-377.	0.5	30

#	Article	IF	Citations
37	Clinical Implementation and Validation of Automated Human Genome Variation Society (HGVS) Nomenclature System for Next-Generation Sequencingâ€“Based Assays for Cancer. Journal of Molecular Diagnostics, 2018, 20, 628-634.	1.2	9
38	DNA testing of pancreatic cyst fluid: is it ready for prime time?. The Lancet Gastroenterology and Hepatology, 2017, 2, 63-72.	3.7	24
39	THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2307-2312.	3.3	58
40	Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. Modern Pathology, 2017, 30, 1133-1143.	2.9	44
41	Guidelines for Validation of Next-Generation Sequencingâ€“Based Oncology Panels. Journal of Molecular Diagnostics, 2017, 19, 341-365.	1.2	524
42	Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. Journal of Molecular Diagnostics, 2017, 19, 4-23.	1.2	1,267
43	Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery, 2017, 161, 168-175.	1.0	56
44	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	1.4	58
45	Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 555-562.	2.3	79
46	NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer, 2016, 122, 1097-1107.	2.0	195
47	Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival. Human Pathology, 2016, 49, 124-134.	1.1	48
48	Next-Generation Sequencing Informatics: Challenges and Strategies for Implementation in a Clinical Environment. Archives of Pathology and Laboratory Medicine, 2016, 140, 958-975.	1.2	70
49	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. JAMA Oncology, 2016, 2, 1023.	3.4	1,192
50	Response of relapsed central nervous system hairy cell leukemia to vemurafenib. Leukemia and Lymphoma, 2016, 57, 2952-2954.	0.6	5
51	Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro-Oncology, 2016, 18, 379-387.	0.6	101
52	A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing. Journal of Molecular Diagnostics, 2016, 18, 165-175.	1.2	66
53	Targeted Next-Generation Sequencing Analysis of a Pendred Syndrome-Associated Thyroid Carcinoma. Endocrine Pathology, 2016, 27, 70-75.	5.2	18
54	American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data. Gastrointestinal Endoscopy, 2016, 83, 1107-1117.e2.	0.5	148

#	Article	IF	Citations
55	Histopathologic and Clinical Characterization of Thyroid Tumors Carrying theBRAF^{K601E}Mutation. Thyroid, 2016, 26, 242-247.	2.4	83
56	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clinical Cancer Research, 2016, 22, 1130-1137.	3.2	166
57	Molecular Characterization of Sporadic Pediatric Thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay. Pediatric and Developmental Pathology, 2016, 19, 115-122.	0.5	63
58	ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma. Oncotarget, 2016, 7, 82943-82952.	0.8	69
59	Molecular Characterization of Apocrine Salivary Duct Carcinoma. American Journal of Surgical Pathology, 2015, 39, 744-752.	2.1	102
60	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid, 2015, 25, 1217-1223.	2.4	344
61	The clinical importance of parathyroid atypia: Is long-term surveillance necessary?. Surgery, 2015, 158, 929-936.	1.0	28
62	Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid. Endocrine Pathology, 2015, 26, 315-319.	5.2	13
63	Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome. Human Pathology, 2015, 46, 1616-1625.	1.1	55
64	Serrated lesions of the appendix frequently harbor KRAS mutations and not BRAF mutations indicating a distinctly different serrated neoplastic pathway in the appendix. Human Pathology, 2014, 45, 227-235.	1.1	55
65	SeqReporter. Journal of Molecular Diagnostics, 2014, 16, 11-22.	1.2	26
66	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 nextâ€generation sequencing assay. Cancer, 2014, 120, 3627-3634.	2.0	445
67	Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4233-4238.	3.3	230
68	MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. Journal of Molecular Endocrinology, 2014, 52, 181-189.	1.1	86
69	Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro-Oncology, 2014, 16, 1478-1483.	0.6	64
70	Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1852-E1860.	1.8	412
71	MicroRNA Expression Array Identifies Novel Diagnostic Markers for Conventional and Oncocytic Follicular Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1-E7.	1.8	99
72	Comprehensive MicroRNA Expression Profiling Identifies Novel Markers in Follicular Variant of Papillary Thyroid Carcinoma. Thyroid, 2013, 23, 1383-1389.	2.4	117

#	Article	IF	Citations
73	LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. Clinical Cancer Research, 2013, 19, 1816-1826.	3.2	70
74	Molecular genetics and diagnosis of thyroid cancer. Nature Reviews Endocrinology, 2011, 7, 569-580.	4.3	798
75	MicroRNA Dysregulation in Human Thyroid Cells Following Exposure to Ionizing Radiation. Thyroid, 2011, 21, 261-266.	2.4	39
76	MicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma. Annals of Surgical Oncology, 2011, 18, 2035-2041.	0.7	216
77	Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3390-3397.	1.8	712
78	Molecular Diagnostics of Gliomas. Archives of Pathology and Laboratory Medicine, 2011, 135, 558-568.	1.2	67
79	miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Modern Pathology, 2010, 23, 1577-1582.	2.9	129
80	Molecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2092-2098.	1.8	674
81	Molecular Diagnostics and Predictors in Thyroid Cancer. Thyroid, 2009, 19, 1351-1361.	2.4	296
82	Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery, 2009, 146, 1215-1223.	1.0	149
83	MicroRNA Expression Profiles in Thyroid Tumors. Endocrine Pathology, 2009, 20, 85-91.	5.2	110
84	Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Review of Molecular Diagnostics, 2008, 8, 83-95.	1.5	259
85	MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic Utility. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1600-1608.	1.8	552
86	Detection of Clonal IGH Gene Rearrangements: Summary of Molecular Oncology Surveys of the College of American Pathologists. Archives of Pathology and Laboratory Medicine, 2007, 131, 185-189.	1.2	16
87	Examination of Chromosome 1p Alterations in Glioblastomas. FASEB Journal, 2007, 21, A393.	0.2	0
88	Prevalence ofRET/PTCRearrangements in Thyroid Papillary Carcinomas: Effects of the Detection Methods and Genetic Heterogeneity. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3603-3610.	1.8	202
89	Detection of SYT-SSX Rearrangements in Synovial Sarcomas by Real-Time One-Step RT-PCR. Pediatric and Developmental Pathology, 2005, 8, 162-167.	0.5	9
90	Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. Journal of Clinical Investigation, 2005, 115, 94-101.	3.9	371

#	Article	IF	Citations
91	Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters, 2004, 209, 1-6.	3.2	152
92	BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5399-5404.	1.8	950
93	RASPoint Mutations and PAX8-PPARÎ³ Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2318-2326.	1.8	664
94	Molecular Profile and Clinical-Pathologic Features of the Follicular Variant of Papillary Thyroid Carcinoma. American Journal of Clinical Pathology, 2003, 120, 71-77.	0.4	370
95	High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research, 2003, 63, 1454-7.	0.4	1,132
96	PAX8-PPARÎ³ Rearrangement in Thyroid Tumors. American Journal of Surgical Pathology, 2002, 26, 1016-1023.	2.1	346
97	Prevalence of RET/PTC Rearrangements in Hashimoto's Thyroiditis and Papillary Thyroid Carcinomas. International Journal of Surgical Pathology, 2002, 10, 15-22.	0.4	126